# A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02597049` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02597049](<https://clinicaltrials.gov/study/NCT02597049>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02597049

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.

## Technical summary

Registry record NCT02597049. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-02 (actual). Results posted on 2018-04-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 424 participants (enrolled count; ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Start date: 2015-11 (registry gives no type) (ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Results first posted: 2018-04-27 (ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Countries: United States; Austria; Czechia; Germany; Hungary; Israel; Mexico; Puerto Rico; Spain (ClinicalTrials.gov record NCT02597049, source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02597049-2020-06-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- Acronym: AWARD-10
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Placebo
- Intervention (Drug): SGLT2 inhibitor
- Intervention (Drug): Metformin
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial (`cardio:pubmed-29483060`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 585e2e52035bdab8e54ed231dbc44d9e36bd1d6ee9e6e45ddd19c35486bd7a9d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
